DocGo Future Growth
Future criteria checks 1/6
DocGo's revenue is forecast to decline at 0.7% per annum while its annual earnings are expected to grow at 109.1% per year. EPS is expected to grow by 109.1% per annum. Return on equity is forecast to be 35.6% in 3 years.
Key information
109.1%
Earnings growth rate
109.07%
EPS growth rate
| Healthcare earnings growth | 18.5% |
| Revenue growth rate | -0.7% |
| Future return on equity | 35.64% |
| Analyst coverage | Good |
| Last updated | 25 Mar 2026 |
Recent future growth updates
Recent updates
DCGO: Transport EBITDA Outlook Will Drive Future Upside Potential
Analysts recently trimmed their DocGo price targets, with cuts such as Stifel's move from $4.00 to $2.50, citing mixed Q4 results, modestly higher 2026 transport guidance, and updated expectations for growth, margins, and P/E assumptions. Analyst Commentary Bullish analysts acknowledge the recent price target cuts but still point to several areas they see as supportive for DocGo's valuation and long term execution story.
DCGO: Transport EBITDA And 2026 Guidance Will Drive Future Upside Potential
Narrative Update Analysts have nudged their price expectations for DocGo lower, trimming aggregate targets by around $0.10 as they factor in mixed Q4 results, modestly higher 2026 transport guidance, and updated views on margins, growth, and future P/E multiples. Analyst Commentary Recent Street commentary on DocGo is mixed, with some analysts focusing on potential value in the transport segment and others reacting to lower price targets and Q4 variability.DCGO: Transport EBITDA Outlook Will Support Future Upside Potential
Narrative Update The analyst price target for DocGo has been reduced from $4.00 to $2.50, as analysts factor in mixed Q4 results while crediting modestly higher 2026 transport guidance and the view that the transport unit alone could potentially support proceeds above the current share price. Analyst Commentary Recent research reflects a more cautious stance on DocGo, with the price target reduced to US$2.50 while still crediting specific strengths in the transport segment.
DCGO: Future Returns Will Rely On Expanding Telehealth Weight Loss Services
Analysts have trimmed their price targets on DocGo to reflect slightly softer revenue growth assumptions, along with somewhat stronger profit margin and future P/E expectations, resulting in only a modest adjustment to their overall valuation view. What's in the News Nasdaq notified DocGo on January 26, 2026 that the company is not in compliance with the $1.00 minimum bid price requirement.DCGO: Buyback Extension And Telehealth Expansion Will Support Future Upside
Analysts have trimmed their price targets on DocGo to $2.50, citing slightly higher discount rate assumptions, a modestly softer profit margin outlook, and a higher future P/E multiple as key drivers of the revised view. What's in the News Nasdaq notified DocGo on January 26, 2026 that the company is not in compliance with the minimum US$1.00 bid price requirement, triggering a 180 day window until July 27, 2026 to regain compliance before potential further action is considered (Delistings).DCGO: Future Returns Will Rely On Expanding Longitudinal Virtual Weight Loss Care
Analysts have slightly reduced their price target on DocGo, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. This adjustment signals a more cautious stance on the company’s risk and earnings profile.DCGO: Buyback Extension And M&A Pipeline Will Support Future Upside
Analysts have trimmed their price target on DocGo to reflect a fair value shift from about $3.08 to roughly $2.50. The change reflects updated assumptions around revenue contraction, slightly higher required returns, modestly better profit margins, and a lower future P/E multiple.DCGO: Future Returns Will Depend On Expanding Longitudinal Care Partnerships
Analysts have made a small upward tweak to their price target on DocGo, reflecting slightly more constructive assumptions around revenue growth and long term profit margins, while keeping the projected P/E and discount rate almost unchanged. What's in the News Robbins Geller Rudman & Dowd LLP announced a proposed US$12.5 million cash settlement in the DocGo securities class action, subject to court approval at a hearing scheduled for March 24, 2026 in the Southern District of New York (Lawsuits & Legal Issues).DCGO: Future Returns Will Depend On Longitudinal Care And Maturing Revenue Mix
Analysts have nudged up their price target on DocGo by a modest amount, citing slightly higher long term profit margin expectations and a marginally richer future earnings multiple. Together, these factors support a small increase in estimated fair value.DCGO: Future Returns Will Depend On New Longitudinal Care Contracts
Analysts have lowered their price target on DocGo from approximately 1.60 dollars to 1.00 dollars, citing a higher required discount rate and a reduced valuation multiple, despite modest improvements in the projected revenue trajectory and profit margins. What's in the News DocGo signaled an active mergers and acquisitions strategy, highlighting its ability to acquire traditional health care assets and layer on its technology and mobile health capabilities to support long-term growth and shareholder value (company commentary) The company provided updated guidance, forecasting 2025 revenue of 315 million to 320 million dollars, including 68 million to 70 million dollars from migrant-related contracts, and 2026 revenue of 280 million to 300 million dollars with no migrant-related revenue (corporate guidance) DocGo recorded a goodwill impairment charge of approximately 8.7 million dollars in the third quarter of 2025, reflecting a write-down of acquired assets (company filing) DocGo announced a new Longitudinal Care Services program with a California-based insurer, targeting 10,000 under-engaged members with combined telehealth and in-home clinical services starting in the fourth quarter (client announcement) The company is expanding its partnership with a national insurer in New Mexico, launching care gap closure and planned primary care services for 10,000 Turquoise Care members through at-home visits and chronic care support (client announcement) Valuation Changes The fair value estimate has fallen significantly from approximately $1.60 to $1.00 per share.Benign Growth For DocGo Inc. (NASDAQ:DCGO) Underpins Its Share Price
Sep 26
DocGo Inc. (NASDAQ:DCGO) Looks Inexpensive After Falling 38% But Perhaps Not Attractive Enough
May 16Is It Too Late To Consider Buying DocGo Inc. (NASDAQ:DCGO)?
Apr 16We Like The Quality Of DocGo's (NASDAQ:DCGO) Earnings
Mar 06These 4 Measures Indicate That DocGo (NASDAQ:DCGO) Is Using Debt Safely
Mar 01Subdued Growth No Barrier To DocGo Inc. (NASDAQ:DCGO) With Shares Advancing 33%
Feb 11
Innovative Health Initiatives Promise Growth Amid Analysts' Concerns Over Future Earnings And Margins
Strategic partnerships with virtual-only providers and operational efficiency improvements indicate a comprehensive approach to expanding health solutions and improving margins.DocGo Inc. (NASDAQ:DCGO) Doing What It Can To Lift Shares
Aug 05At US$3.40, Is DocGo Inc. (NASDAQ:DCGO) Worth Looking At Closely?
Jul 17These 4 Measures Indicate That DocGo (NASDAQ:DCGO) Is Using Debt Safely
Jun 11DocGo: Upside Remains Attractive After Share Price Decline
Mar 20Does DocGo (NASDAQ:DCGO) Have A Healthy Balance Sheet?
Feb 13DocGo: Good Performance, Trust Issues
Feb 05Why DocGo Inc. (NASDAQ:DCGO) Could Be Worth Watching
Jan 25Fewer Investors Than Expected Jumping On DocGo Inc. (NASDAQ:DCGO)
Jan 04Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 319 | -19 | N/A | N/A | 5 |
| 12/31/2026 | 299 | -32 | N/A | N/A | 6 |
| 12/31/2025 | 322 | -182 | 27 | 34 | N/A |
| 9/30/2025 | 368 | -52 | 52 | 58 | N/A |
| 6/30/2025 | 436 | -18 | 81 | 87 | N/A |
| 3/31/2025 | 521 | -1 | 84 | 91 | N/A |
| 12/31/2024 | 617 | 20 | 65 | 70 | N/A |
| 9/30/2024 | 695 | 31 | 43 | 51 | N/A |
| 6/30/2024 | 743 | 30 | -34 | -26 | N/A |
| 3/31/2024 | 703 | 22 | -60 | -52 | N/A |
| 12/31/2023 | 624 | 7 | -74 | -64 | N/A |
| 9/30/2023 | 534 | 7 | -75 | -67 | N/A |
| 6/30/2023 | 452 | 6 | -23 | -14 | N/A |
| 3/31/2023 | 436 | 20 | -20 | -13 | N/A |
| 12/31/2022 | 441 | 35 | 23 | 29 | N/A |
| 9/30/2022 | 453 | 50 | 23 | 29 | N/A |
| 6/30/2022 | 435 | 50 | 24 | 29 | N/A |
| 3/31/2022 | 387 | 36 | 11 | 18 | N/A |
| 12/31/2021 | 319 | 24 | -9 | -2 | N/A |
| 9/30/2021 | 229 | -4 | -2 | 4 | N/A |
| 6/30/2021 | 170 | -10 | -15 | -9 | N/A |
| 3/31/2021 | 130 | -10 | -13 | -7 | N/A |
| 12/31/2020 | 94 | -14 | -17 | -11 | N/A |
| 12/31/2019 | 48 | -20 | -18 | -14 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DCGO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DCGO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DCGO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DCGO's revenue is expected to decline over the next 3 years (-0.7% per year).
High Growth Revenue: DCGO's revenue is forecast to decline over the next 3 years (-0.7% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DCGO's Return on Equity is forecast to be high in 3 years time (35.6%)
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/03 03:12 |
| End of Day Share Price | 2026/05/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DocGo Inc. is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sarah James | Barclays |
| David Larsen | BTIG |
| Richard Close | Canaccord Genuity |